Meanwhile, the BH3 mimetic ABT-199 (venetoclax), a specific Bcl-2 inhibitor, has been approved by the Food and Drug Administration (2018) and the European Medicines Agency (2021), for clinical use in CLL and AML [33]. This evidence concerns the gene BCL2 and acute myeloid leukemia.